𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of teniposide in advanced breast cancer

✍ Scribed by Janne Boas; Dorte Rasmussen; Ole Paaske Hansen; Svend Aage Engelholm; Per Dombernowsky

Publisher
Springer
Year
1990
Tongue
English
Weight
177 KB
Volume
25
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase II study of peptichemio in advan
A phase II study of peptichemio in advanced breast cancer
✍ V. Hug; G. N. Hortobagyi; A. U. Buzdar; G. R. Blumenschein; W. Grose; M. A. Burg πŸ“‚ Article πŸ“… 1980 πŸ› John Wiley and Sons 🌐 English βš– 445 KB πŸ‘ 3 views
A phase II study of oral idarubicin (4-d
A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
✍ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl πŸ“‚ Article πŸ“… 1988 πŸ› Springer 🌐 English βš– 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s

A phase II study of high-dose medroxypro
A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer
✍ Geoffrey Falkson; HΓ¨ndrΓ© C. Falkson πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high